285
NCCN 临床指南-NSCLC Non-Small Cell Lung Cancer 非小细胞肺癌-2022.v3中文版.pdf
DavidS. Ettinger, 医学博士/主席†The Sidney Kimmel ComprehensiveCancer Center JohnsHopkins* Douglas E. Wood
291
NCCN 临床指南-NSCLC Non-Small Cell Lung Cancer 非小细胞肺癌-2023.v1.pdf
NCCN 临床指南-NSCLC Non-Small Cell Lung Cancer 非小细胞肺癌-2023.v1NCCN 临床指南-NSCLC Non-Small Cell Lung Cancer 非小细胞肺癌-2023.v1NCCN 临床指南-NSCLC Non-Small Cell Lung Cancer 非小细胞肺癌-2023.v1
21
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer (NXPowerLite 副本) (1).pdf
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer (NXPowerLite 副本) (1)The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer (NXPowerLite 副本) (1)The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer (NXPowerLite 副本) (1)
254
临床实际指南-非小细胞肺癌Non-Small Cell Lung NCCN 4.2021.docx
临床实际指南-非小细胞肺癌Non-Small Cell Lung NCCN 4.2021临床实际指南-非小细胞肺癌Non-Small Cell Lung NCCN 4.2021临床实际指南-非小细胞肺癌Non-Small Cell Lung NCCN 4.2021
257
NCCN -non-small cell lung cancer 2021.pdf
NCCN -non-small cell lung cancer 2021NCCN -non-small cell lung cancer 2021NCCN -non-small cell lung cancer 2021
257
NCCN -Non-Small Cell Lung Cancer-2021v5.pdf
NCCN -Non-Small Cell Lung Cancer-2021v5NCCN -Non-Small Cell Lung Cancer-2021v5NCCN -Non-Small Cell Lung Cancer-2021v5
234
小细胞肺癌 Non-Small Cell Lung Cancer v1.2021 (Chinese).pdf
小细胞肺癌 Non-Small Cell Lung Cancer v1.2021 (Chinese)小细胞肺癌 Non-Small Cell Lung Cancer v1.2021 (Chinese)小细胞肺癌 Non-Small Cell Lung Cancer v1.2021 (Chinese)
48
iressa-(gefitinib)-in-the-treatment-of-advanced-non-small-cell-lung-cancer-(nsclc)ppt课件.ppt
iressa-(gefitinib)-in-the-treatment-of-advanced-non-small-cell-lung-cancer-(nsclc)ppt课件
23
The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer.pdf
The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancerThe gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancerThe gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer
18
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103) A Randomized Phase II Study.pdf
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103) A Randomized Phase II StudyErlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103) A Randomized Phase II StudyErlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103) A Randomized Phase II Study

向豆丁求助:有没有Non-Small?

95%的用户最终下载了:
如要投诉违规内容,请联系我们按需举报;如要提出意见建议,请到社区论坛发帖反馈。